Show simple item record

dc.contributor.authorCantón-Bulnes, María Luisa
dc.contributor.authorGarcía Garmendia, José Luis
dc.contributor.authorEstella García, Ángel 
dc.contributor.authorFernández-Galilea, Adela
dc.contributor.authorBlanco, Isidro
dc.contributor.authorEstecha-Foncea, María Antonia
dc.contributor.authorGordillo-Resina, Marina
dc.contributor.authorRodríguez-Gómez, Jorge
dc.contributor.authorPineda-Capitán, Jesús
dc.contributor.authorMartínez-Fernández, Carmen
dc.contributor.authorEscoresca-Ortega, Ana
dc.contributor.authorAmaya Villar, Rosario
dc.contributor.authorMora-Ordóñez, Juan
dc.contributor.authorGonzález-Soto, Sara
dc.contributor.authorGarnacho-Montero, José
dc.contributor.otherCirugíaes_ES
dc.contributor.otherMedicinaes_ES
dc.date.accessioned2026-10-30T08:46:18Z
dc.date.available2026-10-30T08:46:18Z
dc.date.issued2026
dc.identifier.issn1435-4373
dc.identifier.issn0934-9723
dc.identifier.urihttp://hdl.handle.net/10498/40512
dc.description.abstractObjectives: The aim of this study was to validate the SeptiCyte® RAPID assay, a molecular test to distinguish sepsis from sterile inflammation, by determining its diagnostic accuracy in critically ill patients who meet criteria for sepsis according to Sepsis-3 definition on ICU admission Design: This is an observational, prospective, and multicenter study.Setting: Carried out in seven hospitals in Andalusia (Spain). A 2.5 mL whole blood sample was collected and tested in a SeptiCyte RAPID kit on a real time PCR platform (IdyllaTM). A score from 0 to 15 (SeptiScore™) was generated that falls into four bands based on the increasing likelihood of infection-positive systemic inflammation. Patients: Patients aged 18 years or older, admitted to the ICU with a diagnosis of sepsis.Main results: We enrolled 354 patients, of whom 86 (24.3%) did not present sepsis at the researchers´ discretion. SeptiCyte® RAPID showed an AUC of [0.84 (CI95% 0.79-0.87)] for differentiating sepsis from sterile systemic inflammation. SeptiCyte® RAPID was significantly better for sepsis diagnosis than CRP [0.75 (CI95% 0.70-0.80)] (p =0.003) but without significant differences with PCT [0.80 (CI95% 0.75-0.84)]. SeptiScore distribution in patients with sepsis was higher than patients with sterile inflammation, with a PPV of 68.8% and 92.2% (Bands 3 and 4) for sepsis diagnosis and a PPV of 100% for sterile inflammation (Band 1). Independent risk factors for sepsis were estimated probability of sepsis [OR 8.02 (CI 95% 4.50-14.28), p<0.001], SeptiScore [OR 1.64 (CI 95% 1.35-1.99), p<0.001], and log procalcitonin [OR 1.68 (CI 95% 1.09-2.59), p=0.020].Conclusions: SeptiCyte® RAPID discriminates sepsis from sterile inflammation in critically ill adults, adding value to the diagnosis of sepsis. Purpose: The aim of this study was to validate the SeptiCyte® RAPID assay, a molecular test to distinguish sepsis from sterile inflammation, by determining its diagnostic accuracy in critically ill patients who meet criteria for sepsis according to Sepsis-3 definition on ICU admission.Methods: This is an observational, prospective, and multicenter study. Carried out in seven hospitals in Andalusia (Spain). A 2.5 mL whole blood sample was collected and tested in a SeptiCyte RAPID kit on a real time PCR platform (IdyllaTM). A score from 0 to 15 (SeptiScore™) was generated that falls into four bands based on the increasing likelihood of infection-positive systemic inflammation.Patients aged 18 years or older, admitted to the ICU with a diagnosis of sepsis were included. Results: We enrolled 353 patients, of whom 86 (23.7%) did not present sepsis at the researchers´ discretion. SeptiCyte® RAPID showed an AUC of [0.84 (CI95% 0.79-0.87)] for differentiating sepsis from sterile systemic inflammation. SeptiCyte® RAPID was significantly better for sepsis diagnosis than CRP [0.75 (CI95% 0.70-0.80)] (p =0.003) but without significant differences with PCT [0.80 (CI95% 0.75-0.84)]. SeptiScore distribution in patients with sepsis was higher than patients with sterile inflammation, with a PPV of 68.8% and 92.2% (Bands 3 and 4) for sepsis diagnosis and a PPV of 100% for sterile inflammation (Band 1). Independent risk factors for sepsis were physicians´ subjective likelihood of sepsis [intermediate probabilty OR 4.55 (95% CI 1.61-12.83), p=0.004 and high probabilty OR 72.04 (95% CI 20.85-248.93), p<0.001], SeptiScore [OR 1.65 (95% CI 1.32-2.07), p<0.001], and log procalcitonin [OR 1.74 (95% CI 1.08-2.79), p=0.022].Conclusions: SeptiCyte® RAPID discriminates sepsis from sterile inflammation in critically ill adults, adding value to the diagnosis of sepsis.es_ES
dc.formatapplication/pdfes_ES
dc.language.isoenges_ES
dc.publisherSpringer Science and Business Media Deutschland GmbHes_ES
dc.rightsAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.sourceEuropean Journal of Clinical Microbiology and Infectious Diseases - 2026, Vol. 45 n.6 pp. 1605-1615es_ES
dc.subjectBiomarkerses_ES
dc.subjectDiagnosis accuracyes_ES
dc.subjectICUes_ES
dc.subjectMortalityes_ES
dc.subjectSepsises_ES
dc.subjectSeptycitees_ES
dc.titleDiagnostic accuracy of SeptiCyte® RAPID to discriminate sepsis from non-infectious critical illness in patients meeting sepsis criteria according to sepsis-3 definition at ICU admissiones_ES
dc.typejournal articlees_ES
dc.rights.accessRightsopen accesses_ES
dc.identifier.doi10.1007/S10096-026-05431-6
dc.type.hasVersionVoRes_ES


Files in this item

This item appears in the following Collection(s)

Show simple item record

Atribución 4.0 Internacional
This work is under a Creative Commons License Atribución 4.0 Internacional